ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: ADVANTAGES OF CALCIUM ANTAGONISTS
https://doi.org/10.20996/1819-6446-2008-4-5-39-45
Abstract
Aim. To study effect of antihypertensive therapy with amlodipine maleat (Stamlo® M, “Dr. Reddy’s”, India) on morphofunctional heart indices, intensity of systemic inflammation and oxidative stress in patients with arterial hypertension (HT) with chronic obstructive pulmonary disease (COPD).
Material and methods. 20 patients with COPD II-III stage (GOLD 2006) in remission and HT 1-2 stage were involved in the study. Morphofunctional heart indices, respiratory function, levels of C-reactive protein (CRP) and oxidative stress (lipid peroxidation products (LPP) – acilhydroperoxides) were evaluated.
Results. Amlodipine maleat therapy provides target level of blood pressure (BP) according to ambulatory BP monitoring with improvement of pathological type of daily BP profile. Reduction of diastolic dysfunction of left and right ventricles was revealed. Therapy was safe in terms of respiratory function. Significant CRP and LPP levels reduction was observed.
Conclusion. Amlodipine maleat therapy has high antihypertensive effect, organoprotective properties and safety in hypertensive patients with COPD. Besides this therapy demonstrates systemic anti-inflammatory action and reduces oxidative stress.
About the Authors
T. V. Adasheva
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
I. V. Fedorova
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
V. S. Zadionchenko
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
M. V. Macievich
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
V. V. Lee
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
S. V. Pavlov
Moscow State University of Medicine and Density, Delegatskaya ul. 20, stroen. 1, Moscow, 127473 Russia
Russian Federation
Russian Federation
References
1. Шальнова С.А., Деев А.В., Оганов Р.Г., Шестов Д.В. Роль систолического и диастолического артериального давления для прогноза смертности от сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика 2002:(1):1-15.
2. Erdine S. How well is hypertension controlled in Europe? European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2007;8(3):1-2.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
4. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514–9.
5. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol 1998;27:962-9.
6. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333- 9.
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26.
8. Глезер Г.А., Глезер М.Г. Артериальная гипертония, М., 1996.
9. Жданов В.Ф. Клинико-статистическая характеристика больных неспецифическими заболеваниями легких с системной артериальной гипертензией. В: Актуальные проблемы пульмонологии. Сб. научн. тр., Л., 1991, с.89-93.
10. Соодаева С.К. Роль свободно-радикального окисления в патогенезе ХОБЛ. Атмосфера. Пульмонология и аллергология 2002;(1):24-5.
11. Ellerbeck E.F., Jencks S.F., Radford M.J., et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14.
12. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97(10):1094-101.
13. Мухамеджанова Г.Ф. Влияние антигипертензивных и антиангинальных препаратов на органы дыхания. Кардиология 1995;(3):93-6.
14. Котовская Ю.В., Кобалава Ж.Д., Ивлева А.Я. Кашель при лечении ингибиторами ангио- тензинпревращающего фермента. Практикующий врач 1997;(11):12.
15. Goldszer RC, Lilly LS, Solomon HS. Prevalence of cough during angiotensin converting enzyme inhibitor therapy. Am J Med 1988;85:887.
16. Lacourciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors vs angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994;12:S49-S53.
17. Ding Y., Vaziri N.D. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitricoxide synthase expression. J Pharmacol Exp Ther 2000;292:606-9.
18. Задионченко В.С.,Кузьмичева Н.В. Свиридов А.А. Клинико-функциональные особенности артериальной гипертонии при бронхообструктивном синдроме. Тер арх 2000;72(1):51- 5.
19. Mason RP, Mak IT, Trumbore MW, Mason PE. Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999;84:16L-22L.
20. Berkels R, Taubert D, Bartels H, et al. Amlodipine increases endothelial nitric oxide by dual mechanismus. Pharmacology 2004; 70:39-45.
21. Cominacini L, Pasini AF, Pastorino AM, et al. Comparative effects of different dihydropyridines on the expression of adhession molecules induced by TNF-alpha on endothelial cells. J Hypertens 1999;17:1837-41.
22. Cominacini L, Garbin U, Fratta Pacini A, et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997;15:1633-40.
23. Федорова И.В., Мациевич М.В. Клинико-функциональные особенности артериальной гипертонии при хронической обструктивной болезни легких. В: Материалы XXX итоговой конференции общества молодых ученых МГМСУ. М., 2008. с.343-344.
24. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836– 43.
25. Repine J.E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:341-57.
26. Ланкин В.З. Метаболизм липоперекисей в тканях млекопитающих. В: Биохимия липидов и их роль в обмене веществ. М.: Наука, 1981; с. 75–95.
Review
For citations:
Adasheva T.V., Fedorova I.V., Zadionchenko V.S., Macievich M.V., Lee V.V., Pavlov S.V. ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: ADVANTAGES OF CALCIUM ANTAGONISTS. Rational Pharmacotherapy in Cardiology. 2008;4(5):39-45. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-5-39-45
Views:
994
Email this article 